BioWa Announces Extended Licensing to MedImmune of BioWa's POTELLIGENT(R) Technology for Use in Antibody Research And Development

BioWa Announces Extended Licensing to MedImmune of BioWa's POTELLIGENT(R) Technology for Use in Antibody Research And Development

October 25, 2007

    PRINCETON, N.J., Oct. 25 /Xinhua-PRNewswire/ -- BioWa,
Inc. (BioWa) announced today that it has entered into a
second agreement with MedImmune to provide additional
access to BioWa's patented POTELLIGENT(R) Technology
platform for the development of antibody-dependent cellular
cytotoxicity (ADCC) enhanced antibodies. 

    The agreement grants to MedImmune non-exclusive license
rights to develop, manufacture and market antibodies based
on POTELLIGENT(R) Technology for an undisclosed number of
targets.  In return, BioWa receives from MedImmune certain
fees and milestone payments during product development, as
well as royalties on marketed products using ADCC enhanced
antibodies.

    "We are pleased to extend our relationship with
MedImmune, a world-leading biologics business and the
cornerstone to AstraZeneca's plans to establish a major
international presence in the research and development of
biological therapeutics," said Dr. Masamichi Koike,
President and CEO of BioWa. "With MedImmune's superior
expertise in antibody-based drug development, this
collaboration complements BioWa's mission to bring about
the benefit of POTELLIGENT(R) Technology to patients as
quickly as possible."

    About POTELLIGENT(R) Technology 

    POTELLIGENT(R) Technology improves potency and efficacy
of antibody therapeutics, by enhancing antibody-dependent
cellular cytotoxicity (ADCC), one of the major mechanism of
antibody therapeutics.  POTELLIGENT(R) Technology involves
the reduction of the amount of fucose in the carbohydrate
structure of an antibody using a proprietary
fucosyltransferase-knockout CHO cell line as a production
cell.  Research shows that POTELLIGENT(R) Technology
significantly enhances ADCC activity of an antibody in
vitro, thereby increasing the potential for improved
activity in vivo.  

    About BioWa, Inc.

    BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo
Co., Ltd., Japan's pharmaceutical and largest biotech
company, and is the exclusive worldwide licensor of
POTELLIGENT(R) Technology, which creates high ADCC
monoclonal antibodies.  Currently, BioWa is developing ADCC
enhanced monoclonal antibody-based therapeutics to fight
cancer and other life-threatening and debilitating diseases
and both BioWa and Kyowa have POTELLIGENT(R) antibody
products in various clinical stages.  BioWa creates and
develops enhanced ADCC antibodies for itself and others,
offering a full range of antibody discovery and development
capabilities.  For more information about BioWa, visit its
web site at www.biowa.com.

    POTELLIGENT(R) is the trademark of Kyowa Hakko Kogyo
Co., Ltd.  All rights are reserved.


    For more information, please contact:

    BioWa, Inc.
    Masamichi Koike, Ph.D
    President and CEO 
    Phone: [phone]

    Martina Molsbergen
    Vice President, Business Management
    Phone: [phone]